Detalhe da pesquisa
1.
TCR-independent CD137 (4-1BB) signaling promotes CD8+-exhausted T cell proliferation and terminal differentiation.
Immunity
; 56(7): 1631-1648.e10, 2023 07 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-37392737
2.
Eomes-Dependent Loss of the Co-activating Receptor CD226 Restrains CD8+ T Cell Anti-tumor Functions and Limits the Efficacy of Cancer Immunotherapy.
Immunity
; 53(4): 824-839.e10, 2020 10 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-33053331
3.
CD155 on Tumor Cells Drives Resistance to Immunotherapy by Inducing the Degradation of the Activating Receptor CD226 in CD8+ T Cells.
Immunity
; 53(4): 805-823.e15, 2020 10 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-33053330
4.
The receptors CD96 and CD226 oppose each other in the regulation of natural killer cell functions.
Nat Immunol
; 15(5): 431-8, 2014 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-24658051
5.
RAS/RAFlandscape in monoclonal plasma cell conditions.
Blood
; 2024 Apr 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-38643494
6.
SAR442085, a novel anti-CD38 antibody with enhanced antitumor activity against multiple myeloma.
Blood
; 139(8): 1160-1176, 2022 02 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-35201323
7.
Cancer immunoediting and immune dysregulation in multiple myeloma.
Blood
; 136(24): 2731-2740, 2020 12 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-32645135
8.
TIGIT immune checkpoint blockade restores CD8+ T-cell immunity against multiple myeloma.
Blood
; 132(16): 1689-1694, 2018 10 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-29986909
9.
Imprinting of Mesenchymal Stromal Cell Transcriptome Persists even after Treatment in Patients with Multiple Myeloma.
Int J Mol Sci
; 21(11)2020 May 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-32481768
10.
NK cells require IL-28R for optimal in vivo activity.
Proc Natl Acad Sci U S A
; 112(18): E2376-84, 2015 May 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-25901316
11.
High endothelial venule blood vessels for tumor-infiltrating lymphocytes are associated with lymphotoxin ß-producing dendritic cells in human breast cancer.
J Immunol
; 191(4): 2001-8, 2013 Aug 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-23825314
12.
DNAM-1 control of natural killer cells functions through nectin and nectin-like proteins.
Immunol Cell Biol
; 92(3): 237-44, 2014 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-24343663
13.
Stimulated γδ T cells increase the in vivo efficacy of trastuzumab in HER-2+ breast cancer.
J Immunol
; 187(2): 1031-8, 2011 Jul 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-21670311
14.
Phosphoantigens overcome human TCRVgamma9+ gammadelta Cell immunosuppression by TGF-beta: relevance for cancer immunotherapy.
J Immunol
; 184(12): 6680-7, 2010 Jun 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-20483742
15.
How tumors might withstand γδ T-cell attack.
Cell Mol Life Sci
; 68(14): 2433-42, 2011 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-21547501
16.
Toll-like receptor 4 selective inhibition in medullar microenvironment alters multiple myeloma cell growth.
Blood Adv
; 6(2): 672-678, 2022 01 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-34714910
17.
Hospicells derived from ovarian cancer stroma inhibit T-cell immune responses.
Int J Cancer
; 126(9): 2143-52, 2010 May 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-19739080
18.
A regulatory cross-talk between Vgamma9Vdelta2 T lymphocytes and mesenchymal stem cells.
Eur J Immunol
; 39(3): 752-62, 2009 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-19197941
19.
Human peripheral blood DNAM-1neg NK cells are a terminally differentiated subset with limited effector functions.
Blood Adv
; 3(11): 1681-1694, 2019 06 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-31167820
20.
Chemotherapy followed by anti-CD137 mAb immunotherapy improves disease control in a mouse myeloma model.
JCI Insight
; 52019 06 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-31194697